Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Price (London, United Kingdom), V. Kouranos (London, United Kingdom), K. Dimopoulos (London, United Kingdom), C. Mccabe (London, United Kingdom), A. Kempny (London, United Kingdom), L. Price (London, United Kingdom), G. Costola (London, United Kingdom), C. Harries (London, United Kingdom), E. Renzoni (London, United Kingdom), P. Molyneaux (London, United Kingdom), M. Kokosi (London, United Kingdom), T. Maher (London, United Kingdom), F. Chua (London, United Kingdom), P. George (London, United Kingdom), A. Wells (London, United Kingdom), S. Wort (London, United Kingdom). Sarcoidosis-associated Pulmonary Hypertension: A London Cohort. 304

Member's Comments

No comment yet.

Related content which might interest you: Portopulmonary hypertension in United Kingdom: A contemporary, national, observational study Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Pulmonary Hypertension in Childhood Source: Virtual Congress 2020 – From the bronchoscope to the clinic: paediatric bronchology at a glance Year: 2020 Pulmonary Arterial Hypertension Research Award Source: Annual Congress 2009 - Pulmonary Arterial Hypertension Research Award (supported by Actelion Pharmaceuticals) Year: 2009 Pulmonary Arterial Hypertension Research Award Source: Annual Congress 2008 - Pulmonary Arterial Hypertension Research Award (supported by Actelion Pharmaceuticals) Year: 2008 Long-term data from the Swiss pulmonary hypertension registry Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Severe Pulmonary Hypertension Management Across Europe (PHAROS): an ERS Clinical Research Collaboration Source: Eur Respir J, 55 (5) 2001047; 10.1183/13993003.01047-2020 Year: 2020 Pulmonary Hypertension Source: Eur Respir Rev 2009; 18: 193-194 Year: 2009 Pulmonary Hypertension Source: Research Seminar 2013 - Optimising models for human lung diseases and drug development Year: 2013 Epoprostenol dosing by concomitant therapies in the PROSPECT registry Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Impact of Pulmonary Hypertension on the Response to Pulmonary Rehabilitation in Obstructive Lung Disease Source: International Congress 2019 – The future of pulmonary rehabilitation discussed today Year: 2019 Isolated hypocapnia: A sign not to be neglected Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Phenotyping Adults with Non-Cystic Fibrosis Bronchiectasis:A 5-Year Cohort Study in a Azerbaijan medical University Center Source: International Congress 2017 – Clinical challenges in chronic lung diseases Year: 2017 PHA-UK living with Pulmonary Hypertension 2016 Survey Source: International Congress 2017 – PAH and CTEPH Year: 2017 Epidemiology of Idiopathic Pulmonary Fibrosis in Australia Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Nebivolol and pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014